Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis, Ocular | 8 | 2019 | 9 | 2.210 |
Why?
|
| Visual Acuity | 12 | 2025 | 216 | 1.540 |
Why?
|
| Uveitis | 7 | 2018 | 38 | 1.350 |
Why?
|
| Antitubercular Agents | 7 | 2019 | 61 | 1.210 |
Why?
|
| Uveitis, Intermediate | 1 | 2017 | 1 | 0.590 |
Why?
|
| Eye Infections, Bacterial | 1 | 2017 | 17 | 0.590 |
Why?
|
| Vitrectomy | 4 | 2024 | 56 | 0.560 |
Why?
|
| Glucocorticoids | 6 | 2018 | 365 | 0.550 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 925 | 0.520 |
Why?
|
| Dexamethasone | 1 | 2017 | 344 | 0.510 |
Why?
|
| Choroiditis | 3 | 2012 | 10 | 0.500 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 201 | 0.490 |
Why?
|
| Young Adult | 20 | 2025 | 6502 | 0.440 |
Why?
|
| Retrospective Studies | 22 | 2025 | 9399 | 0.410 |
Why?
|
| Adolescent | 20 | 2025 | 9411 | 0.380 |
Why?
|
| Retinal Detachment | 3 | 2024 | 69 | 0.340 |
Why?
|
| Retinal Vasculitis | 3 | 2019 | 4 | 0.330 |
Why?
|
| Child | 16 | 2025 | 7273 | 0.320 |
Why?
|
| Tomography, Optical Coherence | 4 | 2018 | 146 | 0.300 |
Why?
|
| Fluorescein Angiography | 6 | 2019 | 103 | 0.300 |
Why?
|
| Retina | 3 | 2024 | 224 | 0.290 |
Why?
|
| Adult | 22 | 2025 | 27147 | 0.280 |
Why?
|
| Follow-Up Studies | 10 | 2024 | 3716 | 0.280 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 61 | 0.280 |
Why?
|
| Middle Aged | 21 | 2025 | 26555 | 0.280 |
Why?
|
| Treatment Outcome | 13 | 2024 | 8436 | 0.270 |
Why?
|
| Aged | 17 | 2025 | 19574 | 0.250 |
Why?
|
| Ophthalmia, Sympathetic | 1 | 2025 | 1 | 0.240 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2024 | 245 | 0.240 |
Why?
|
| Vitreoretinopathy, Proliferative | 1 | 2024 | 5 | 0.230 |
Why?
|
| Male | 22 | 2025 | 43249 | 0.220 |
Why?
|
| Drug Therapy, Combination | 6 | 2019 | 804 | 0.210 |
Why?
|
| Female | 22 | 2025 | 47186 | 0.210 |
Why?
|
| Intravitreal Injections | 3 | 2017 | 79 | 0.190 |
Why?
|
| Vitreous Body | 3 | 2017 | 57 | 0.190 |
Why?
|
| Microsurgery | 2 | 2024 | 93 | 0.180 |
Why?
|
| Takayasu Arteritis | 1 | 2019 | 5 | 0.160 |
Why?
|
| Tertiary Care Centers | 2 | 2017 | 114 | 0.160 |
Why?
|
| Panuveitis | 1 | 2018 | 3 | 0.160 |
Why?
|
| Retinal Diseases | 1 | 2019 | 91 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1374 | 0.150 |
Why?
|
| Aorta, Thoracic | 1 | 2019 | 166 | 0.150 |
Why?
|
| Aqueous Humor | 1 | 2017 | 26 | 0.150 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2018 | 27 | 0.150 |
Why?
|
| Drug Implants | 1 | 2017 | 35 | 0.150 |
Why?
|
| Humans | 22 | 2025 | 91073 | 0.150 |
Why?
|
| Tuberculin Test | 3 | 2012 | 9 | 0.140 |
Why?
|
| Sarcoidosis | 1 | 2018 | 73 | 0.140 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2018 | 59 | 0.140 |
Why?
|
| Forecasting | 1 | 2018 | 307 | 0.140 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 246 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 336 | 0.130 |
Why?
|
| Uveomeningoencephalitic Syndrome | 1 | 2015 | 1 | 0.130 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 328 | 0.130 |
Why?
|
| Choroidal Neovascularization | 1 | 2016 | 34 | 0.130 |
Why?
|
| Endovascular Procedures | 1 | 2019 | 303 | 0.120 |
Why?
|
| Fundus Oculi | 3 | 2019 | 36 | 0.120 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2014 | 8 | 0.110 |
Why?
|
| Optic Disk | 1 | 2014 | 14 | 0.110 |
Why?
|
| Ganciclovir | 1 | 2014 | 50 | 0.110 |
Why?
|
| Eye Abnormalities | 1 | 2014 | 42 | 0.110 |
Why?
|
| Recurrence | 4 | 2019 | 1170 | 0.110 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 143 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 608 | 0.100 |
Why?
|
| Incidence | 3 | 2025 | 1599 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 6847 | 0.100 |
Why?
|
| India | 2 | 2025 | 126 | 0.090 |
Why?
|
| Diabetic Retinopathy | 1 | 2012 | 93 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2682 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2014 | 490 | 0.090 |
Why?
|
| Inflammation | 1 | 2016 | 998 | 0.090 |
Why?
|
| Risk Factors | 2 | 2025 | 5608 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2711 | 0.070 |
Why?
|
| Immunosuppressive Agents | 3 | 2019 | 988 | 0.070 |
Why?
|
| Disease Progression | 1 | 2011 | 1493 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 968 | 0.060 |
Why?
|
| United Kingdom | 1 | 2025 | 168 | 0.060 |
Why?
|
| Antigens, CD19 | 1 | 2024 | 65 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2018 | 3790 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2017 | 2904 | 0.060 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 210 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 2024 | 254 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2025 | 882 | 0.050 |
Why?
|
| Saudi Arabia | 1 | 2018 | 17 | 0.040 |
Why?
|
| Mediastinum | 1 | 2018 | 48 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2017 | 284 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 278 | 0.030 |
Why?
|
| Global Health | 1 | 2018 | 194 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2018 | 166 | 0.030 |
Why?
|
| Intraocular Pressure | 1 | 2016 | 60 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 37 | 0.030 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2015 | 5 | 0.030 |
Why?
|
| Prednisolone | 1 | 2015 | 41 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2015 | 85 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2018 | 554 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 673 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2014 | 84 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1609 | 0.030 |
Why?
|
| Acute Disease | 1 | 2015 | 855 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2024 | 2348 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 303 | 0.030 |
Why?
|
| Vitreous Hemorrhage | 1 | 2012 | 12 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 960 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2012 | 95 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2012 | 269 | 0.020 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2010 | 17 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 409 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 297 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1713 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2785 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2012 | 570 | 0.020 |
Why?
|
| HIV Infections | 1 | 2014 | 865 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1204 | 0.010 |
Why?
|